Under construction – not a live service
Sign in
Taking people in United StatesNo phase

The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment

Key facts

Where
Atlanta, Baton Rouge, Houston, New York, Phoenix, Riverside, Sarasota, and West Covina, United StatesSee the 9 sites

Where in United States

  • Pediatrix Medical Group of GeorgiaAtlanta, United StatesContact: Deena Yowler, NP, CNMTaking people
  • Woman's HospitalBaton Rouge, United StatesContact: Bri Jones, MPHTaking people
  • Pediatrix Medical GroupHouston, United StatesContact: Olaide Ashimi Balogun, MDTaking people
  • UT Physicians Maternal-Fetal MedicineHouston, United StatesContact: Aarti Ramdaney, MS, CGCTaking people
  • Carnegie Imaging for WomenNew York, United StatesContact: Josh LandoTaking people
  • Valley Perinatal ServicesPhoenix, United StatesContact: Research DepartmentTaking people
  • Brar PracticeRiverside, United StatesContact: Shelley Mueller, MS, CGCTaking people
  • Sarasota Memorial Health Care SystemSarasota, United StatesContact: Scarleth Andino-Funez, BSN, RNTaking people
  • San Gabriel Valley Perinatal Medical GroupWest Covina, United StatesContact: Richard Burwick, MDTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
BillionToOne Inc.
Trial code
NCT07643896
Record updated
15 October 2026
Original description
The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.Read full original descriptionShow less

ADVANCE Study: Assay Development and Validation for Pre-Natal and Obstetric Conditions

The goal of the ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) study is to compare the concordance of results of a novel non-invasive circulating fetal cell (CFC) assay to the results of prenatal invasive diagnostic testing or postnatal genetic and clinical diagnosis of the resulting neonate. This is a prospective study of pregnant individuals.

Inclusion: pregnant individuals between 10 and 20 weeks of gestation; singleton gestation.

Exclusion: active cancer.

ClinicalTrials.gov NCT07643896

Under construction, not live – The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment (NCT07643896) – Frontlight Research